Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Fagron NV : Disclosure of received notification


Posted on: 31 Jul 18

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2018 - 7:00am (CET)

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received the following notification.

Notification of JPMorgan Asset Management Holdings Inc., received on 26 July 2018

  • On 26 July 2018, Fagron received a notification that the number of voting rights of JPMorgan Asset Management Holdings Inc., a parent undertaking or a controlling person, crossed the disclosure threshold of 5% on 25 July 2018 as the result of the acquisition of voting securities or voting rights.
  • On the notification date, JPMorgan Asset Management Holdings Inc., through JPMorgan Asset Management (UK) Limited, held a total of 3,724,539 voting rights and 4,406 equivalent financial instruments (right to recall). Based on the denominator of 71,843,904 (total number of voting rights), in total JPMorgan Asset Management Holdings Inc., through JPMorgan Asset Management (UK) Limited, held on the notification date 5.18% of the total number of voting rights while the total position was 5.19%.
  • The full chain of controlled undertakings through which the holding is effectively held: JPMorgan Asset Management Holdings Inc. (100%), JPMorgan Asset Management International Limited (100%), JPMorgan Asset Management Holdings (UK) Limited (100%), JPMorgan Asset Management (UK) Limited (100%).
  • The notifications of JPMorgan Asset Management Inc. can be viewed on investors.fagron.com via this link.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

For more information:
Constantijn van Rietschoten
Chief Communications Officer
Tel. +31 6 53 69 15 85
constantijn.van.rietschoten@fagron.com

Fagron profile
Fagron is a leading global company active in pharmaceutical compounding and focused on delivering personalized pharmaceutical care to hospitals, pharmacies, clinics and patients in 34 countries around the world.

The Belgian company Fagron NV is located in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam (stock market code 'FAGR'). The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

Please open the link below for the press release:

Attachment

GlobeNewswire
globenewswire.com

Last updated on: 31/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.